4 Pages
English
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

'AMD and DR Drug Market Will Reach $6.25 billion in 2015' Predicts new Visiongain Report

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer
4 Pages
English

Description

'AMD and DR Drug Market Will Reach $6.25 billion in 2015' Predicts new Visiongain Report PR Newswire LONDON, November 5, 2012 LONDON, November 5, 2012 /PRNewswire/ -- A new report by visiongain predicts that the world market for AMD and DR drugs will reach $6.25bn in 2015. That revenue forecast and others appear in Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023, published in November 2012. Visiongain is a business information provider based in London, UK. Regeneron's 2011 launch of Eylea (aflibercept) has stimulated the market, proving to be one of the most successful biopharmaceutical launches so far. Eylea is in a three-way battle with Lucentis (ranibizumab; Roche/Novartis) and Avastin (bevacizumab; Roche) for the wet AMD market. Also, the R&D pipeline is strong. Visiongain's study identifies key pipeline candidates including new anti-vascular endothelial growth factor (VEGF) drugs such as Allergan's DARPin, with an extended duration of action, and new eye drop formulations such as Alcon's ESBA1008 and Ohr's Squalamine. Beyond anti-VEGF drugs, the wet AMD pipeline is headed by Ophthotech Corporation's Fovista, a PDGF-B blocker which achieved high efficacy results in phase II as part of a combination therapy. However, the dry AMD and DR segments have even greater market growth possibilities, the report notes.

Subjects

Informations

Published by
Reads 15
Language English

Exrait

'AMD and DR Drug Market Will Reach $6.25 billion in 2015' Predicts new Visiongain Report
PR Newswire LONDON, November 5, 2012
LONDON,November 5, 2012/PRNewswire/ --
A new report byvisiongainpredicts that the world market for AMD and DR drugs will reach$6.25bnin 2015. That revenue forecast and others appear inMacular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023, published inNovember 2012. Visiongain is a business information provider based in London, UK.
Regeneron's 2011 launch of Eylea (aflibercept) has stimulated themarket, proving to be one of the most successful biopharmaceutical launches so far. Eylea is in a three-way battle with Lucentis (ranibizumab; Roche/Novartis) and Avastin (bevacizumab; Roche) for the wet AMD market. Also, the R&D pipeline is strong.
Visiongain's study identifies key pipeline candidates including new anti-vascular endothelial growth factor (VEGF) drugs such as Allergan's DARPin, with an extended duration of action, and new eye drop formulations such as Alcon's ESBA1008 and Ohr's Squalamine. Beyond anti-VEGF drugs, the wet AMD pipeline is headed by Ophthotech Corporation's Fovista, a PDGF-B blocker which achieved high efficacy results in phase II as part of a combination therapy. However, the dry AMD and DR segments have even greater market growth possibilities, the report notes.
James Evans, pharmaceutical industry analyst in visiongain, said: "The DR market has been galvanised by the approval of Lucentis and Alimera's Iluvien in 2012, and there's plenty of room for growth in that segm ent. A 2011 study suggested that over 100 million people worldw ide have DR, and over 21 million of them have diabetic macular oedema (DME), so that's a huge patient population.
"The real unmet need, though, is dry AMD, where there are still no drug treatment options. MacuCLEAR have reached phase III trials, and Alcon completed a phase III trial of Tandospirone in 2012. Beyond that, there's a massive range of approaches being tried, including blocking the complement cascade and modulating the visual cycle, on to things like neuroprotectants and regenerative medicine. Advanced Cell Technology's trial in dry AMD is now the leading embryonic stem cell candidate therapy in the clinic.
"In wet AMD, Eylea has made a massive impact, and looks likely to take nearly a third of the whole AMD and DR market by 2015. It isn't incredibly different to Lucentis, but has even greater VEGF-binding affinity and is a significant salvage option. A lot will come down to whether Bayer can get Eylea to mount the same challenge to Lucentis outside the US, with EU and Japan approvals coming inSeptember 2012, and how fast Eylea can add new indications. Lucentis will be the first into most of the retinal submarkets, like central retinal vein occlusion. But the evidence so far is Eylea is a very competitive alternative, once it catches up."
The study forecasts that the AMD and DR market will continue to expand rapidly to 2023, with wet AMD treatment moving beyond anti-VEGF monotherapy, and treatment options emerging for the first time in dry AMD and DR.
Visiongain's report shows revenue forecasts to 2023 at overall world market, therapeutic submarket, product and national level. It forecasts these world-level subm arkets:
Wet AMD Dry AMD DR.
The investigation predicts revenues of leading drugs in the retinal disorders market: Lucentis, Eylea and Avastin. Research, data and analyses cover activities of Roche, Novartis, Pfizer, Regeneron, Allergan and other pharmaceutical companies.
That study discusses R&D and commercial news, shows research interviews and predicts revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, UK, Spain, Italy and the BRIC group.
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023 please visit http://www.visiongain.com/Report/924/Macular-Degeneration-%28AMD%29-and-Diabetic-Retinopathy-%28DR%29-World-Drug-Market-2013-2023
For an executive summary please contact: Email: Sara Peerun onsara.peerun@visiongainglobal.com Tel: +44 (0) 20 7336 6100
Companies Listed Abbott Laboratories Acucela Adnexus Advanced Cell Technology Alcon Alexion Alimera Sciences Alkeus Pharmaceuticals Allegro Ophthalmics Allergan AMD Alliance International American Academy of Ophthalmology (AAO) American Society of Retina Specialists (ASRS) Applied Genetic Technologies Association for Research in Vision and Ophthalmology (ARVO) AstraZeneca Athenagen Atlantis Pharma ATON Pharma Avalanche Biotechnologies Bausch & Lomb Bayer Bayer Yakuhin (Bayer subsidiary) Biogen Idec Biovail Corporation Bristol-Myers Squibb Casey Eye Institute at Oregon Health and Science University Chengdu Kanghong Biotech Columbia University CoMentis Eli Lilly Emory University ESBATech European Court of Justice European Medicines Agency (EMEA/EMA) Eyetech Food and Drug Administration (US FDA) Formatech ForSight Labs ForSight VISION4 Fovea Genaera Gene Signal Genentech GenVec Genzyme Geron Gerot Lannach GlaxoSmithKline Human Genome Sciences iCo Therapeutics Icon Bioscience Innovations in Sight Institute of Ocular Pharmacology ISTA Pharmaceuticals Jerini John Hopkins University Kaplan Medical Center Lions Eye Institute Lpath Ludwig-Maximilians - University of Munich MacuCLEAR MacuSight
Mayo Clinic MedImmune Merck & Co. Mesoblast Molecular Partners Mystic Pharmaceuticals National Eye Institute (US) National Institute for Health and Clinical Excellence (NICE, UK) National Institutes of Health (NIH, US) Natur Produk Neuron Systems Neurotech Novagali Pharma Novartis Numoda Capital Innovations Oakwood Laboratories OcuSciences OHR Pharmaceutical Oklahoma Medical Research Foundation Ophthotech Corporation OPKO Health Ora Bio OraPharma Österreichische Agentur für Gesundheit und Ernährungssicherheit, AGES Othera Pharmaceuticals Otsuka Pharmaceutical Oxford BioMedica Oxigene Paloma Pharmaceuticals Palomid Pharmaceuticals PanOptica PDL BioPharma Pedinol Pharmacal Pele Nova Biotecnologica Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) Pieris Potentia Pharmaceuticals Prevent Blindness America Probiotica Laboratorios pSivida Purdue University QLT Quark Regeneron Retina Macula Institute RetroSense Therapeutics ReVision Therapeutics Roche Sanofi Santen Pharmaceuticals Sanwa Kagaku Kenkyusho SARcode Bioscience Shire Singapore Eye Research Institute (SERI) Singapore National Eye Centre Sirion Therapeutics Sirna Therapeutics StemCells Stemedica Cell Technologies Symphony ViDA Takeda TargeGen Teva Pharmaceutical Industries ThromboGenics UCB University College London (UCL) University of California, Los Angeles University of Florida University of Kentucky College of Medicine University of Michigan Valeant Pharmaceuticals International Varinel Vitreoretinal Technologies
World Health Organization (WHO)
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.comor call her on +44(0)207-336-6100